Trevi Therapeutics, Inc. (TRVI): Cash & Equivalents
$18.91M
As of 2025-12-31
$54.30M
As of 2026-06-30
+14.5%
3-year compound annual growth
-15.9%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $18.91M | -44.5% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $34.10M | +5.2% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $32.40M | +157.3% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $12.59M | -65.8% | 2024-03-20, Balance as of period end |
| 2021-12-31 | $36.83M | -18.2% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $45.00M | -21.5% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $57.31M | +695.8% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $7.20M | n/a | 2020-03-16, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Trevi Therapeutics, Inc. (TRVI) | 2025-12-31 | $18.91M | -44.5% |
| Adicet Bio, Inc. (ACET) | 2025-12-31 | $38.92M | -31.1% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $80.88M | +45.8% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $110.75M | -35.6% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $79.38M | +38.6% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $34.33M | -48.5% |
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | $176.48M | +4.9% |
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | $179.97M | +84.1% |
| COMPASS Pathways plc (CMPS) | 2025-12-31 | $149.61M | -9.4% |
Compare TRVI, ACET, FHTX, URGN side by side · Screen every company in Pharmaceutical Preparations ↗